Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21141930 | 0.84 | MEN1 (0.44) | ALDH1A1CTSLCTSBCTSKTSHR | |
| SCHEMBL21828142 | 0.84 | MEN1 (0.44) | ALDH1A1CTSLCTSBCTSKTSHR | |
| SCHEMBL21827417 | 0.84 | MEN1 (0.44) | ALDH1A1CTSLCTSBCTSKTSHR | |
| SCHEMBL20594278 | 0.82 | SIGMAR1 (0.53) | ALDH1A1DRD4KDM4EDRD2TSHR | |
| SCHEMBL21920972 | 0.82 | SIGMAR1 (0.53) | ALDH1A1DRD4KDM4EDRD2TSHR | |
| SCHEMBL38659290 | 0.81 | SLC6A2 (0.44) | CTSLCTSBCTSKCYP2C19HTR1A | |
| SCHEMBL3828650 | 0.80 | KDM4E (0.47) | ALDH1A1GRIN2BGRM5CTSLCTSB | |
| SCHEMBL3828648 | 0.80 | KDM4E (0.47) | ALDH1A1GRIN2BGRM5CTSLCTSB | |
| SCHEMBL8620387 | 0.79 | MAPT (0.48) | MAPTALDH1A1GRIN2BDRD2 | |
| SCHEMBL30510 | 0.77 | SLC6A2 (0.53) | MAPTALDH1A1GRIN2BDRD4MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695449-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2019-02-21 | — | — | US | disclosed |
| US-10098974-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-10058625-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-08-28 | — | — | US | disclosed |
| US-20150283273-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| US-20150132223-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-05-14 | — | — | US | disclosed |
| US-9017724-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2015-04-28 | — | — | US | disclosed |
| US-8900550-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2610234-A1 | Catalytic radiofluorination | The General Hospital Corporation (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130115168-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| EP-1725269-B1 | CATALYTIC RADIOFLUORINATION | GEN HOSPITAL CORP (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8257680-B1 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120207677-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2012-08-16 | — | — | US | disclosed |
| EP-2388017-A2 | Catalytic radiofluorination | The General Hospital Corporation (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040117-B2 | Closed loop negative feedback system with low frequency modulated gain | FLEXTRONICS AP, LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100215578-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-7632485-B2 | Catalytic radiofluorination | MASSACHUSETTS GENERAL HOSPITAL (US) | 2009-12-15 | — | — | US | disclosed |
| WO-2008022319-A2 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20050260130-A1 | Arylphosphonium compounds containing fluorine-18 that are useful as imaging agents; in particular, the phosphonium compound is a tetraaryl phosphonium salt, [F-18]-(4-fluorophenyl)triphenylphosphonium nitrate; Position Emission Tomography | MASSACHUSETTS GENERAL HOSPITAL (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115168-A1 | Catalytic Radiofluorination | ARSA, STS, KCNK18 | MAPT 4632/4885ALDH1A1 1308/4885GRIN2B 4059/4885 |
| US-10098974-B2 | Catalytic radiofluorination | ARSA, STS, KCNK18 | MAPT 4632/4885ALDH1A1 1308/4885GRIN2B 4059/4885 |
| US-10058625-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | MAPT 4437/4885ALDH1A1 1427/4885GRIN2B 4487/4885 |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | KCNJ5, KCNQ5, KCNK18 | MAPT 4437/4885ALDH1A1 1427/4885GRIN2B 4487/4885 |
| US-20050260130-A1 | Arylphosphonium compounds containing fluorine-18 that are useful as imaging agents; in particular, the phosphonium compound is a tetraaryl phosphonium salt, [F-18]-(4-fluorophenyl)triphenylphosphonium nitrate; Position Emission Tomography | KCNK18, KCNJ5, KCNQ5 | MAPT 2899/4885ALDH1A1 3071/4885GRIN2B 3399/4885 |
| US-20150283273-A1 | Catalytic Radiofluorination | KCNJ5, KCNQ5, KCNK18 | MAPT 4437/4885ALDH1A1 1427/4885GRIN2B 4487/4885 |
| US-10695449-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | MAPT 4437/4885ALDH1A1 1427/4885GRIN2B 4487/4885 |
| US-20100215578-A1 | Catalytic Radiofluorination | KCNJ5, KCNQ5, KCNK18 | MAPT 4437/4885ALDH1A1 1427/4885GRIN2B 4487/4885 |
| US-20150132223-A1 | Catalytic Radiofluorination | ARSA, KCNK18, STS | MAPT 4620/4885ALDH1A1 1178/4885GRIN2B 3857/4885 |
| US-20120207677-A1 | CATALYTIC RADIOFLUORINATION | ARSA, STS, KCNK18 | MAPT 4632/4885ALDH1A1 1308/4885GRIN2B 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.